

CADTH

APRIL 23 TO 25, 2017 | OTTAWA, ON

2017 CADTH SYMPOSIUM

MEASURING VALUE IN THEORY AND THE REAL WORLD



PRELIMINARY PROGRAM

(As of March 31, 2017)

Time		Activity
SUNDAY, APRIL 23, 2017		
0800 to 1900		Registration Desk Open
0800 to 0900		Morning Workshop Registration
0900 to 1200		Workshop AM-1 An Introduction to Health Technology Assessment <i>Introductory. Will be of particular interest to patients, students, and people new to health technology assessment (HTA).</i> <ul style="list-style-type: none">• Dr. Thanh Nguyen, Institute of Health Economics• Nancy Sikich, Health Quality Ontario• Dr. Laura Weeks, CADTH
		Workshop AM-2 Incorporating Heterogeneity Into Economic Evaluation: A Workshop Based on the Revised (Fourth Edition) CADTH Guidelines for Economic Evaluation of Health Technologies: Canada <i>Advanced. Will be of particular interest to health economists.</i> <ul style="list-style-type: none">• Dr. Doug Coyle, University of Ottawa• Karen Lee, CADTH
		Workshop AM-3 How Can Policy-Makers and Clinicians Trust the Results of a Network Meta-Analysis? A Workshop on How to Apply the International Society For Pharmacoeconomics and Outcomes Research (ISPOR) Tool <i>Introductory. Will be of particular interest to policy-makers and clinicians.</i> <ul style="list-style-type: none">• Dr. Andrea Tricco, Li Ka Shing Knowledge Institute, St. Michael's Hospital• Dr. Areti Angeliki Veroniki, Li Ka Shing Knowledge Institute, St. Michael's Hospital
		Workshop AM-4 How Should We Argue About Ethics and Value? Applied Philosophy for Health Technology Assessment <i>Intermediate. Will be of particular interest to HTA producers.</i> <ul style="list-style-type: none">• Ken Bond, CADTH

Time		Activity
		<ul style="list-style-type: none"> • Matthew Barker, Concordia University • Katherine Duthie, Alberta Health Services
		<p>Workshop AM-5 Decision Modelling Using R <i>Intermediate. Will be of particular interest to health economists, decision modellers, and researchers.</i></p> <ul style="list-style-type: none"> • Dr. Petros Pechlivanoglou, Hospital for Sick Children Research Institute
		<p>Workshop AM-6 Using the OncoSim Family of Microsimulation Models to Evaluate Cancer Control Strategies <i>Intermediate. Will be of particular interest to policy-makers, health economists, researchers, and clinicians.</i></p> <ul style="list-style-type: none"> • William Flanagan, Statistics Canada • Dr. Keiko Asakawa, Statistics Canada • Prof. Michael Wolfson, University of Ottawa • Dr. Bill Evans, McMaster University • Natalie Fitzgerald, Canadian Partnership Against Cancer • Saima Memon, Canadian Partnership Against Cancer • Dr. Cindy Gauvreau, Canadian Partnership Against Cancer
		<p>Workshop AM-7 Measuring and Valuing Patient Preferences in Randomized Clinical Trials <i>Introductory. Will be of particular interest to HTA producers and health care professionals.</i></p> <ul style="list-style-type: none"> • Dr. Feng Xie, McMaster University
		<p>Workshop AM-8 Clearer Communication and Plain-Language Writing: Making Health Research Make Sense <i>Intermediate. Will be of interest to all audiences.</i></p> <ul style="list-style-type: none"> • Dr. Janice Mann, CADTH
1200 to 1300		<p>Afternoon Workshop Registration</p>
1300 to 1600		<p>Workshop PM-1 Making Tough Decisions: An Interactive Deliberative Exercise <i>Introductory. Will be of particular interest to patients, students, and people new to HTA.</i></p> <ul style="list-style-type: none"> • Sarah Berglas, CADTH • Ken Bond, CADTH • Frank Gavin, Public Member, CADTH Canadian Drug Expert Committee • Mirhad Lončar, CADTH • Valerie McDonald, Patient Member, CADTH pan-Canadian Oncology Drug Review Expert Review Committee (pERC) • Brad Mitchelmore, CADTH • Jo Nanson, Patient Member, pERC • Tamara Rader, CADTH
		<p>Workshop PM-2 Quantifying and Presenting Uncertainty: A Workshop Based on the Revised (Fourth Edition) CADTH Guidelines for Economic Evaluation of Health Technologies: Canada <i>Advanced. Will be of particular interest to health economists.</i></p> <ul style="list-style-type: none"> • Prof. Christopher McCabe, University of Alberta • Mike Paulden, University of Alberta

Time		Activity
		<ul style="list-style-type: none"> • Karen Lee, CADTH
		<p>Workshop PM-3 The State of Affairs in Health Technology Reassessment: An Interactive Workshop <i>Introductory. Will be of particular interest to health care system decision-makers, producers, and health care professionals.</i></p> <ul style="list-style-type: none"> • Lesley Soril, University of Calgary • Dr. Fiona Clement, University of Calgary • Dr. Stirling Bryan, University of British Columbia • Dr. Tammy Clifford, CADTH • Marc Pelletier, Institute for Health System Transformation & Sustainability
		<p>Workshop PM-4 From Lingo to Application: Use of Confounder Summary Scores (Propensity Scores and Disease Risk Scores) in Health Technology Assessment <i>Introductory. Will be of particular interest to HTA producers.</i></p> <ul style="list-style-type: none"> • Dr. Jason Guertin, McMaster University • Dr. Mina Tadrous, Ontario Drug Policy Research Network
		<p>Workshop PM-5 Early Health Technology Assessment Case Study of Pre-Market Evaluation <i>Intermediate. Will be of particular interest to HTA producers.</i></p> <ul style="list-style-type: none"> • Dr. Murray Krahn, Toronto Health Economics and Technology Assessment (THETA) Collaborative • Dr. Valeria Rac, THETA Collaborative • Dr. Petros Pechlivanoglou, Hospital for Sick Children Research Institute • Dr. Lusine Abrahamyan, THETA Collaborative
		<p>Workshop PM-6 Getting to Know the pan-Canadian Pharmaceutical Alliance <i>Intermediate. Will be of interest to all audiences.</i></p> <ul style="list-style-type: none"> • Imran Ali, pan-Canadian Pharmaceutical Alliance • Sang Mi Lee, pan-Canadian Pharmaceutical Alliance
		<p>Workshop PM-7 Economic Evaluation Using Person-Level Data: Bridging Theory to Practice <i>Intermediate. Will be of particular interest to HTA producers, researchers, and health care professionals.</i></p> <ul style="list-style-type: none"> • Dr. Wanrudee Isaranuwachai, St. Michael's Hospital • Dr. Kednapa Thavorn, The Ottawa Hospital Research Institute
		<p>Workshop PM-8 Making Rational Drug Therapy Decisions at the Point of Care <i>Introductory. Will be of interest to all audiences.</i></p> <ul style="list-style-type: none"> • Brent Jensen, RxFiles Academic Detailing • Dr. Roland Halil, University of Ottawa • Dr. Jay Mercer, Family Physician
1700 to 1900		<p>Welcome Reception and Scientific Poster Exhibition</p> <ul style="list-style-type: none"> • Dr. Brian O'Rourke, President and CEO, CADTH • Dr. Terrence Sullivan, Chair, CADTH Board of Directors

Time		Activity
MONDAY, APRIL 24, 2017		
0730 to 1700		Registration Desk Open
0800 to 0900		Breakfast
0900 to 0930		OFFICIAL OPENING <ul style="list-style-type: none"> • Dr. Brian O'Rourke, President and CEO, CADTH
0930 to 1045		OPENING PLENARY Measuring Value in Theory and the Real World <i>The opening plenary will explore how different stakeholders define and measure value: what it means to them, what they value and why, and how they measure value both in theory and in the real world.</i> <ul style="list-style-type: none"> • Prof. Christopher McCabe, Capital Health Chair in Emergency Medicine Research, Adjunct Professor, Department of Economics, and Adjunct Professor, School of Public Health, University of Alberta • Dr. Bettina Ryll, Founder, Melanoma Patient Network Europe • Tom Maston, Deputy Minister of Health, Government of New Brunswick • Dianne Carmichael, President and CEO, Carmichael Worldwide • Dr. Ken Milne, Chief of Staff, South Huron Hospital. Creator of the knowledge translation project, The Skeptics' Guide to Emergency Medicine
1045 to 1115		Refreshment Break
1115 to 1230		Concurrent Session A1 — Panel Discussion The Value of Drug Policy to Decrease the Costs and Consequences of Inappropriate Prescribing <ul style="list-style-type: none"> • Dr. Justin Turner, Institut universitaire de gériatrie de Montréal • Prof. Jay Shaw, Women's College Hospital Institute for Health System Solutions and Virtual Care • Dr. James Silvius, Alberta Health Services • Marnie Mitchell, Health Canada
		Concurrent Session A2 — Panel Discussion Medical Devices: Generating and Using Real-World Observational Data for Decision-Making on Value <ul style="list-style-type: none"> • Dr. Tammy Clifford, CADTH • Dr. Jessica Jalbert, LA-SER Group and Weill Cornell Medical College • Dr. Laura Hatfield, Harvard Medical School • Dr. Patricia Trbovich, University Health Network and University of Toronto • Mark Campbell, National Institute for Health and Care Excellence (NICE)
		Concurrent Session A3 — Panel Discussion PRISM: Informing Canadian Rare Disease Drug Policy Through Research <ul style="list-style-type: none"> • Prof. Devidas Menon, University of Alberta • Dr. Tania Stafinski, University of Alberta • Dr. Aidan Hollis, University of Calgary • Dr. Durhane Wong-Rieger, Canadian Organization for Rare Disorders • Chad Mitchell, Alberta Health Services • David Lee, Health Canada • Dr. Judith Glennie, Promoting Rare Disease Innovations Through Sustainable Mechanisms (PRISM)

Time		Activity
		<p>Concurrent Session A4 — Panel Discussion Where Is the Value in Broadening the Evaluative Space of Outcome Measurement in Health Technology Assessment?</p> <ul style="list-style-type: none"> • Dr. David Whitehurst, Simon Fraser University • Prof. Jeffrey Hoch, University of California • Dr. Fiona Clement, University of Calgary • Logan Trenaman, University of British Columbia
		<p>Concurrent Session A5 — Panel Discussion The Future of Scientific Advice in Canada</p> <ul style="list-style-type: none"> • Simon Yungler, F. Hoffmann-La Roche Canada • Dr. Amy Sood, CADTH • Dr. Jens Grueger, Roche Pharmaceuticals • Dr. Cathy Parker, Health Canada • Don Husereau, Institute of Health Economics
		<p>Concurrent Session A6 — Panel Discussion Value Frameworks for Cancer Therapies: Are they Useful in the Context of Canadian Health Technology Assessments and Reimbursement Decisions?</p> <ul style="list-style-type: none"> • Barry Stein, Colorectal Cancer Association of Canada • Matthew Brougham, Brougham Consulting and Laser Analytica • Alexandra Chambers, CADTH • Kathy Gesy, Saskatchewan Cancer Agency • Dr. Reiner Banken, Reiner Banken Consulting • Elizabeth Cobbs, Merck
		<p>Concurrent Session A7 — Panel Discussion The Role of Artificial Intelligence in Canada’s Health Care Sector</p> <ul style="list-style-type: none"> • Mike Monteith, ThoughtWire • Graeme Moffat, InteraXon • Brandon Frey, Deep Genomics • Dianne Carmichael, Carmichael Worldwide and Council of Canadian Innovators
		<p>Concurrent Session A8 — Panel Discussion INESSS: Improving the Value of Health Care by Combining Knowledge-Based Evidence With Real-World Experience</p> <ul style="list-style-type: none"> • Dr. Luc Boileau, Institut national d’excellence en santé et en services sociaux (INESSS) • Dr. Catherine Truchon, INESSS • Laurie Lambert, INESSS • Dr. Melanie Tardif, INESSS
1230 to 1330		Lunch

Time		Activity
1330 to 1445		<p>Concurrent Session B1 — Oral Presentations</p> <p>PATIENT AND PUBLIC ENGAGEMENT</p> <p>Public and Patient Engagement in Canadian Drug Assessment: 10 Years of Experience in Ontario and at the CADTH Common Drug Review</p> <ul style="list-style-type: none"> • Prof. Katherine Boothe, McMaster University <p>Patient and Public Engagement in Health Technology Assessment: An Update of a Systematic Review of International Experiences</p> <ul style="list-style-type: none"> • Prof. Marie-Pierre Gagnon, Université Laval <p>Bringing the Voice of Patients Into Health Technology Assessment at Health Quality Ontario</p> <ul style="list-style-type: none"> • Mark Weir, Health Quality Ontario
		<p>Concurrent Session B2 — Oral Presentations</p> <p>APPROPRIATE USE</p> <p>Reaching and Engaging the Elderly in Deprescribing</p> <ul style="list-style-type: none"> • Janet Currie, Canadian Deprescribing Network <p>Economic Evaluation of Disinvestment in Hydroxyethyl Starches for Coronary Artery Bypass Surgery</p> <ul style="list-style-type: none"> • Dr. Ava John-Baptiste, Western University <p>Evidence Uninformed: Venous Thromboembolism Prophylaxis for Medical Patients as a Required Organizational Practice</p> <ul style="list-style-type: none"> • Dr. Aaron Tejani, University of British Columbia
		<p>Concurrent Session B3 — Oral Presentations</p> <p>MEDICAL IMAGING: DIAGNOSTIC AND INTERVENTIONAL RADIOLOGY</p> <p>Proton Beam Therapy: Making Decisions on Out-of-Country Referrals</p> <ul style="list-style-type: none"> • Andra Morrison, CADTH <p>Value in Diagnostic Imaging</p> <ul style="list-style-type: none"> • Dr. Martin Reed, Children’s Hospital, Winnipeg <p>Reducing Imaging Tests for Low Back Pain: Can Patients Choose Wisely?</p> <ul style="list-style-type: none"> • Dr. Nick Bansback, University of British Columbia <p>The Canadian Medical Imaging Inventory: Past, Present, and Future</p> <ul style="list-style-type: none"> • Alison Sinclair, CADTH
		<p>Concurrent Session B4 — Oral Presentations</p> <p>PHARMACEUTICAL POLICY</p> <p>Impact of the Reduction of Generic Drug Prices Policy on Adherence to Medication</p> <ul style="list-style-type: none"> • Fidela Mushashi, University of British Columbia <p>Potential Savings From Biosimilars in Canada</p> <ul style="list-style-type: none"> • Gary Warwick, Patented Medicine Prices Review Board <p>Mergers and Acquisitions and Generics: The Impacts of This Forgotten Factor on Pricing and Shortages</p> <ul style="list-style-type: none"> • Prof. Marc-André Gagnon, University of Ottawa Centre for Health Law, Policy, and Ethics <p>National Regional Health Authority Formulary Collaborative</p> <ul style="list-style-type: none"> • Jeremy Slobodan, Alberta Health Services

Time		Activity
		<p>Concurrent Session B5 — Oral Presentations HEALTH TECHNOLOGY ASSESSMENT METHODS Harmonization of Health Technology Assessment Methods: The Pan-Canadian Experience</p> <ul style="list-style-type: none"> • Nancy Sikich, Health Quality Ontario <p>A Canadian Population-Grouping Methodology: Profiling Health Utilization Across Sectors</p> <ul style="list-style-type: none"> • Yvonne Rosehart, Canadian Institute for Health Information <p>A Collaborative Approach to Assessing the Potential Value of Innovative Technologies</p> <ul style="list-style-type: none"> • Geneviève Plamondon, Institut national d'excellence en santé et services sociaux (INESSS) <p>An Efficient Solution and Implementation of the Decision Tree Problem</p> <ul style="list-style-type: none"> • Dr. Petros Pechlivanoglou, Hospital for Sick Children Research Institute
		<p>Concurrent Session B6 — Oral Presentations REAL-WORLD EVIDENCE: PHARMACEUTICALS The Alzheimer's Drug Therapy Initiative (ADTI): Drug Coverage With Evidence Development in British Columbia</p> <ul style="list-style-type: none"> • Dr. Elaine Chong, British Columbia Ministry of Health <p>Pattern and Policy Reflections on a 12-Year Utilization Review of Insulin and Blood Glucose Test Strip Use in Manitoba</p> <ul style="list-style-type: none"> • Dr. Jamie Falk, University of Manitoba <p>Keeping it Real: Utilization of Real-World Data Sources to Generate Real-World Evidence for Better Evidence-Based Decision-Making</p> <ul style="list-style-type: none"> • Dr. Tarry Ahuja, Eli Lilly Canada <p>Modelling the Cost-Effectiveness of Rituximab Use Compared With Tumour Necrosis Factor Inhibitors (Anti-TNF) Drugs as a Second-Line Therapy in Patients With Rheumatoid Arthritis in Quebec, Canada Using RHUMADATA Registry Data</p> <ul style="list-style-type: none"> • Dr. Elena Lopatina, University of Calgary
		<p>Concurrent Session B7 — Oral Presentations GENOMICS Patient Preferences and Perceived Utility of Incidental Genomic Sequencing Results</p> <ul style="list-style-type: none"> • Dr. Yvonne Bombard, St. Michael's Hospital and University of Toronto <p>Risk-Based Versus Age-Based Breast Cancer Screening: The Role of Genetic Information</p> <ul style="list-style-type: none"> • Steve Gribble, University of Ottawa <p>Mapping the Cost Trajectory of the Diagnostic Odyssey for Children With Undiagnosed but Suspected Genetic Conditions</p> <ul style="list-style-type: none"> • Dr. Nick Dragojlovic, University of British Columbia
1445 to 1515		Refreshment Break

Time		Activity
1515 to1630		<p>Concurrent Session C1 — Panel Discussion Canada’s Multi-Stakeholder Approach to Drug Shortages</p> <ul style="list-style-type: none"> • Dr. Elaine Chong, British Columbia Ministry of Health • Michael Carter, Health Canada
		<p>Concurrent Session C2 — Panel Discussion Reimbursement Perspectives on Precision Medicine</p> <ul style="list-style-type: none"> • Ferg Mills, Innomar Strategies • Olaf Koester, OHWK Business Management Advisory • Dr. David Shum, F. Hoffmann-La Roche Canada • Dr. Natasha Leighl, Princess Margaret Cancer Centre
		<p>Concurrent Session C3 — Panel Discussion How Do We Use Health Technology Assessment and Real-World Evidence to Implement “Reassessments” Effectively?</p> <ul style="list-style-type: none"> • Dr. Christina Farup, Johnson & Johnson • Dr. Tammy Clifford, CADTH • Prof. Jeffrey Hoch, University of California • Chad Mitchell, Alberta Health Services
		<p>Concurrent Session C4 — Panel Discussion Call for Patient Input . . . Again</p> <ul style="list-style-type: none"> • Sarah Berglas, CADTH • David Wells, Health Quality Ontario • Zal Press, Patient Commando Productions • Michael Houlahan, Sand Pile Inc. • Pujita Vaidya, US Food and Drug Administration • Laurie Proulx, Canadian Arthritis Patient Alliance
		<p>Concurrent Session C5 — Panel Discussion Getting Past PowerPoint Slides and Putting Real-World Evidence Into Action</p> <ul style="list-style-type: none"> • Jessica Arias, Cancer Care Ontario • Jaclyn Beca, Cancer Care Ontario • Angie Wong, Ontario Ministry of Health and Long-Term Care • Dr. Kelvin Chan, Sunnybrook Health Sciences Centre Odette Cancer Centre
		<p>Concurrent Session C6 — Panel Discussion Precision Medicine: Applying Theory to Practice for Value With Companion Diagnostics (CDx)</p> <ul style="list-style-type: none"> • Dr. Don Juzwishin, Alberta Health Services • Prof. Christopher McCabe, University of Alberta • Dr. Tania Bubela, University of Alberta • Dr. Judith Hugh, University of Alberta and Alberta Health Services
		<p>Concurrent Session C7 — Panel Discussion CADTH Health Economics Guidelines: What’s New?</p> <ul style="list-style-type: none"> • Karen Lee, CADTH • Dr. Elizabeth McCarron, CADTH • Prof. Stirling Bryan, School of Population and Public Health, University of British Columbia • Dr. Doug Coyle, University of Ottawa • Dr. Murray Krahn, Toronto Health Economics and Technology Assessment (THETA) Collaborative • Prof. Christopher McCabe, University of Alberta

Time		Activity
		<p>Concurrent Session C8 — Panel Discussion Incorporating Indigenous Perspectives into Health Technology Management</p> <ul style="list-style-type: none"> • Valerie Gideon, First Nations and Inuit Health Branch, Health Canada • Dr. Marcia Anderson, University of Manitoba • Kathy Perrin, Government of Nunavut
1800 to 2200		<p>Social Event: A Night at the Museum <i>In keeping with Canada's 150th anniversary, the Canadian Museum of History is the centrepiece for this evening of discovery, Canadian-inspired food, and upbeat entertainment. Special presentation by Dr. Danielle Martin, author of Better Now: Six Big Ideas to Improve Health Care for All Canadians.</i></p>
TUESDAY, APRIL 25, 2017		
0700 to 1700		Registration Desk Open
0700 to 0830		Breakfast
0730 to 0830		<p>Breakfast Session 1 The Health Technology Expert Review Panel: Developing Recommendations on the Optimal Use of Medical Devices, Diagnostic Tests, and Procedures</p> <ul style="list-style-type: none"> • Dr. Stirling Bryan, School of Population and Public Health, University of British Columbia • Dr. Hilary Jaeger, Former Surgeon General, Canadian Armed Forces (retired) • Dr. Jeremy Petch, Li Ka Shing Knowledge Institute, St. Michael's Hospital • Chris Kamel, CADTH
		<p>Breakfast Session 2 What I Know Now That I Wish I Had Known Then: A Rapid Mentorship Session on How to Succeed in Health Technology Assessment</p> <ul style="list-style-type: none"> • Shannon Kelly, University of Ottawa • Dr. Doug Coyle, University of Ottawa • Michelle Mujoomdar, CADTH • Dr. George Wells, University of Ottawa • Dr. Sharon Straus, Li Ka Shing Knowledge Institute, St. Michael's Hospital, and University of Toronto
		<p>Breakfast Session 3 Why Did I Do That? A Systemic Evaluation of Factors Contributing to Over-Investigations and Over-Diagnosis</p> <ul style="list-style-type: none"> • Dr. Malvinder Parmar, Northern Ontario School of Medicine
		<p>Breakfast Session 4 Making Treatment Decisions in the Real World Isn't Just Spinning the Wheel of Fortune</p> <ul style="list-style-type: none"> • Linda Wilhelm, Canadian Arthritis Patient Alliance • Donna Thomson, The Caregiver Network • Alan Birch, North York General Hospital • Louise Binder, Canadian Cancer Survivor Network

Time		Activity
		Breakfast Session 5 Health Equity in Guideline Development: New GRADE Guidance <ul style="list-style-type: none"> • Dr. Vivian Welch, Methods Centre, Bruyère Research Institute and School of Epidemiology, Public Health and Preventive Medicine, University of Ottawa
		Breakfast Session 6 Responding to the Opioid Crisis in Canada <ul style="list-style-type: none"> • Dr. Janice Mann, CADTH
		Breakfast Session 7 The Public: How Can It Contribute to an Understanding of and Decisions About the Value of a New Health Technology? <ul style="list-style-type: none"> • Prof. Devidas Menon, University of Alberta • Dr. Jackie Street, University of Adelaide • Dr. Tania Stafinski, University of Alberta • Ken Bond, CADTH
		Breakfast Session 8 An Inside Look at the Early History of the CADTH Common Drug Review <ul style="list-style-type: none"> • Barb Shea, former Vice-President, Common Drug Review, CADTH • Elaine MacPhail, former Director, Common Drug Review, CADTH
0845 to 1000		PLENARY SESSION Meaningful Stakeholder Engagement <i>The panel will explore how and when different stakeholders want to be engaged, and how effective engagement can help achieve high value for the health care system.</i> <ul style="list-style-type: none"> • Dr. Stuart Peacock, Leslie Diamond Chair in Cancer Survivorship at Simon Fraser University and Co-Director of the Canadian Centre for Applied Research in Cancer Control • MJ DeCoteau, Founder and Executive Director, Rethink Breast Cancer • Pamela Fralick, President, Innovative Medicines Canada • Dr. Marcia Anderson, Head, Section of First Nations, Métis and Inuit Health, Max Rady College of Medicine, University of Manitoba • Janet Knox, President and CEO, Nova Scotia Health Authority
1000 to 1030		Refreshment Break
1030 to 1145		Concurrent Session D1 — Oral Presentations ETHICAL, LEGAL, AND SOCIAL ISSUES IN HEALTH TECHNOLOGY ASSESSMENT A Systematic Review of Ethical Issues in the Health Technology Assessment of Ovarian Stimulation and Ovulation Induction: Convergence and Disjuncture <ul style="list-style-type: none"> • Shawn Winsor, McMaster University Medical Assistance in Dying (MAiD): A Scoping Review of International Literature <ul style="list-style-type: none"> • Grace Suva, Registered Nurses' Association of Ontario From Principles of Screening to Principles of Diagnostic Technology: A Dynamic Interpretation of Wilson and Jungner's Principles <ul style="list-style-type: none"> • Prof. Lynette Reid, Dalhousie University Prohibition Infringing on Charter Rights: Examining the Logic Defending Commercial Reproductive Labour and Medical Assistance in Dying <ul style="list-style-type: none"> • Kathryn Morrison, University of Waterloo

Time		Activity
		<p>Concurrent Session D2 — Oral Presentations IMPLEMENTATION Reviewing Implementation Issues in Dialysis: Challenges and Opportunities</p> <ul style="list-style-type: none"> • Eftyhia Helis, CADTH <p>A Systems Approach in the Management of Health Technology: Evaluating Value Through Real-World Evidence</p> <ul style="list-style-type: none"> • Dr. Hameed Khan, Alberta Innovates • Bob Rauscher, MEDEC <p>Using Real-World Evidence to Support Increased Client Access to Health Care via Telehealth</p> <ul style="list-style-type: none"> • Karen Tulk, Western Health, Newfoundland and Labrador <p>Making Informed Technology Decisions: How to Move From “Adoption in Principle” to “Adoption in Practice”</p> <ul style="list-style-type: none"> • Thomas Mullie, Alberta Health Services
		<p>Concurrent Session D3 — Oral Presentations ONCOLOGY Putting Policy Into Practice: Learning From Real-World Implications</p> <ul style="list-style-type: none"> • Charlotte Hoskin, Cancer Care Ontario <p>Generating Population-Based Real-World Evidence in Oncology Drugs</p> <ul style="list-style-type: none"> • Dr. Kelvin Chan, Sunnybrook Health Sciences Centre Odette Cancer Centre <p>Feedback on Economic Models From the CADTH pan-Canadian Oncology Drug Review (pCODR) Expert Committee: An Update</p> <ul style="list-style-type: none"> • Rebecca Hancock-Howard, Amaris
		<p>Concurrent Session D4 — Oral Presentations SURGICAL INTERVENTIONS A Real-Life Evaluation of Implementation Facilitators, Barriers, and Context for the Successful Introduction of a Novel Surgical Procedure: The Direct Anterior Approach for Total Hip Arthroplasty</p> <ul style="list-style-type: none"> • Dr. Paule Poulin, Alberta Health Services <p>The Long-Term Cost-Effectiveness of Bariatric Surgery for the Treatment of Severe Obesity: A Cost-Utility Analysis From a Societal Perspective</p> <ul style="list-style-type: none"> • Dr. Erica Lester, University of Alberta <p>Value in Surgical Quality Improvement Programs: A Real-World Example From The Ottawa Hospital</p> <ul style="list-style-type: none"> • Sasha van Katwyk, The Ottawa Hospital Research Institute
		<p>Concurrent Session D5 — Oral Presentations HEPATITIS C New Oral Hepatitis C Medications: Are They Living up to Their Expectations in a Real-World Setting?</p> <ul style="list-style-type: none"> • Kevin Wilson, Saskatchewan Ministry of Health <p>Model-Based Projection of Health and Economic Effects of Screening Hepatitis C: Informing on Screening Recommendations in Canada</p> <ul style="list-style-type: none"> • Dr. William W.L. Wong, University of Waterloo <p>Health Utilities in Chronic Hepatitis C Patients With Decompensated Cirrhosis or Hepatocellular Carcinoma</p> <ul style="list-style-type: none"> • Yasmin Saeed, University of Toronto <p>Hepatitis C Virus Treatment Prioritization Improves Population Health Outcomes</p> <ul style="list-style-type: none"> • Prof. Lauren Cipriano, Western University

Time		Activity
		<p>Concurrent Session D6 — Oral Presentations</p> <p>OBSTRUCTIVE SLEEP APNEA</p> <p>The Value of Stratified Economic Analysis in Informing Decision-Making: A Case Study of Interventions for Obstructive Sleep Apnea</p> <ul style="list-style-type: none"> • Dr. Bernice Tsoi, CADTH <p>Economic Evaluation of a Portable, Home-Testing Device (BresoDx) for Obstructive Sleep Apnea</p> <ul style="list-style-type: none"> • Dr. Petros Pechlivanoglou, Hospital for Sick Children Research Institute <p>Diagnostic Accuracy of Level IV Portable Sleep Monitors Versus Polysomnography for Obstructive Sleep Apnea: A Systematic Review and Meta-Analysis</p> <ul style="list-style-type: none"> • Dr. Lusine Abrahamyan, Toronto Health Economics and Technology Assessment (THETA) Collaborative and University of Toronto <p>SIESTA Home Sleep Study With BresoDx Portable Monitor for the Diagnosis of Obstructive Sleep Apnea: A Pragmatic Randomized Controlled Trial</p> <ul style="list-style-type: none"> • Dr. Valerie Rac, Toronto Health Economics and Technology Assessment (THETA) Collaborative and University of Toronto
		<p>Concurrent Session D7 — Oral Presentations</p> <p>PHARMACY</p> <p>Costs and Savings Associated With the Pharmacists Prescribing for Minor Ailments Program in Saskatchewan</p> <ul style="list-style-type: none"> • Ellen Rafferty, University of Saskatchewan • Dr. Marwa Farag, University of Saskatchewan • Mohsen Yaghoubi, University of Saskatchewan <p>Economic Analysis of Pharmacist-Administered Influenza Immunizations in Ontario</p> <ul style="list-style-type: none"> • Prof. Daria O'Reilly, McMaster University <p>Screening for Atrial Fibrillation in Canadian Pharmacies Is a Cost-Effective Strategy</p> <ul style="list-style-type: none"> • Dr. Jean-Eric Tarride, McMaster University <p>Do Clinicians Back the Backgrounders? Perceptions and Acceptance of Backgrounders by Pharmacists</p> <ul style="list-style-type: none"> • Jeremy Slobodan, Alberta Health Services
		<p>Concurrent Session D8 — Oral Presentations</p> <p>MEANINGFUL STAKEHOLDER ENGAGEMENT</p> <p>The Matters Approach to Clinical Engagement</p> <ul style="list-style-type: none"> • Lisa Pyke, CADTH • Jennifer Boswell, Health PEI <p>Making Health Technology Assessment Relevant in the Innovation Policy Landscape</p> <ul style="list-style-type: none"> • Mark Campbell, National Institute for Health and Care Excellence (NICE) <p>Evaluation of Patient and Public Involvement Initiatives in Health Technology Assessment: An Environmental Scan</p> <ul style="list-style-type: none"> • Dr. Laura Weeks, CADTH
1145 to 1315		AWARDS LUNCHEON

Time		Activity
1315 to 1430		<p>Concurrent Session E1 — Panel Discussion Assessing the Value of Diagnostic Innovation: A Growing Role for Health Technology Assessment?</p> <ul style="list-style-type: none"> • Dr. Fiona Miller, University of Toronto • Dr. Tammy Clifford, CADTH • Dr. Irfan Dhalla, Health Quality Ontario • Dr. François Rousseau, Université Laval
		<p>Concurrent Session E2 — Panel Discussion Implementing Health Technology–Related Decisions: The Opportunities and Challenges in a Local Health Care Setting</p> <ul style="list-style-type: none"> • Dr. Julie Polisena, CADTH • Dr. Eric Cohen, Sunnybrook Hospital • Dr. Daniel James Niven, University of Calgary • Hal Hilfi, The Ottawa Hospital • Dr. Don Juzwishin, Alberta Health Services
		<p>Concurrent Session E3 — Panel Discussion Use of the Resident Assessment Instrument: Minimum Data Set (RAI-MDS 2.0) and interRAI Long-Term Care Facilities Assessment Systems to Inform Policy and Improve Practice and Health Outcomes in Long-Term Care Residents</p> <ul style="list-style-type: none"> • Selma Didic, Canadian Foundation for Healthcare Improvement • Dr. Kaye Phillips, Canadian Foundation for Healthcare Improvement • Geri St. Louis, Canadian Institute for Health Information • Julie Weir, New Brunswick Association of Nursing Homes
		<p>Concurrent Session E4 — Panel Discussion Fair Pricing of Pharmaceuticals</p> <ul style="list-style-type: none"> • Dr. Eric Lun, British Columbia Ministry of Health • Tanya Potashnik, Patented Medicine Prices Review Board
		<p>Concurrent Session E5 — Panel Discussion To Model or not to Model, What Is the Question?</p> <ul style="list-style-type: none"> • Prof. Jeffrey Hoch, University of California • Dr. Chris Cameron, Cornerstone Research Group • Dr. Jaime Caro, Evidera • Jaclyn Beca, Cancer Care Ontario • Norman Paracha, F. Hoffmann-La Roche
		<p>Concurrent Session E6 — Panel Discussion Creating Criteria Using Patient Experience for High-Cost Rare-Use Drugs With Limited Evidence</p> <ul style="list-style-type: none"> • Michele Evans, Alberta Health Services • Jeremy Slobodan, Alberta Health Services • Dr. James Silvius, Alberta Health Services • Dr. Irvin Mayers, University of Alberta
		<p>Concurrent Session E7 — Panel Discussion New Innovations in Combining Clinical Data and Real-World Evidence to Understand the Long-Term Impact of Therapies: The Future is Here</p> <ul style="list-style-type: none"> • Brad Millson, QuintilesIMS • Charles Victor, Institute for Clinical Evaluative Sciences • Dr. Marie-Claude Laliberté, Abbvie Corporation

Time		Activity
		<ul style="list-style-type: none"> • Tara Gomes, St. Michael's Hospital
1430 to 1500		Refreshment Break
1500 to 1615		<p>CLOSING PLENARY</p> <p>Aligning Regulation and Reimbursement</p> <p><i>An expert panel will discuss the issues, challenges, and opportunities associated with aligning regulatory and reimbursement processes for health technologies more closely so that value is considered earlier in the overall process.</i></p> <ul style="list-style-type: none"> • Brent Fraser, Vice-President, Pharmaceutical Reviews, CADTH • Dr. Hans-Georg Eichler, Senior Medical Officer, European Medicines Agency • Michele Evans, Assistant Deputy Minister, Pharmaceutical & Supplementary Health Benefits Division, Alberta Health Services • John Helou, President, Pfizer Canada • Dr. Robyn Lim, Senior Science Advisor, Health Products and Food Branch, Health Canada
1615 to 1630		<p>OFFICIAL CLOSING</p> <ul style="list-style-type: none"> • Dr. Brian O'Rourke, President and CEO, CADTH